| Heading: |
Drugs: Prices |
| Question ID: |
1805891 |
| UIN: |
HL7810 |
| House: |
Lords |
| Date tabled: |
2025-05-22 |
| Asking Member ID: |
2735 |
| Asking Member display name: |
The Earl of Dundee
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
The Earl of Dundee
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what assessment they have made of multi-indication medicines and their relevance to the NHS, and of the approaches to and pricing of such medicines in other countries. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-04 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Health Service seeks the best value in its commercial deals for patients and taxpayers. The recent NHS Commercial Framework consultation clarified the circumstances in which indication specific pricing will be considered in England. This will... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |